Skip to contentT
Tenax Therapeutics, Inc.
T
TENXTenax Therapeutics, Inc. Q1 2025 · 10-Q
Revenue$0.00$0.00no prior Q1 2024 on file Net Income-$10.41M-$10.41MN/M vs Q1 2024 EPS Diluted-$0.28-$0.28N/M vs Q1 2024 Operating Income-$11,338,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Tenax Therapeutics, Inc. · CIK 34956 · Engraved from SEC EDGAR
ended Mar 31, 2025 · filed May 14, 2025 · 44 d after period end